14.26
price down icon0.56%   -0.08
pre-market  Pre-mercato:  13.61   -0.65   -4.56%
loading

Eton Pharmaceuticals Inc Borsa (ETON) Ultime notizie

pulisher
Apr 20, 2025

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Increase in Short Interest - Defense World

Apr 20, 2025
pulisher
Apr 15, 2025

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Has Found A Path To Profitability - Yahoo Finance

Apr 15, 2025
pulisher
Apr 13, 2025

Raymond James Financial Inc. Makes New Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World

Apr 13, 2025
pulisher
Apr 09, 2025

Retail investors who have a significant stake must be disappointed along with institutions after Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) market cap dropped by US$35m - simplywall.st

Apr 09, 2025
pulisher
Apr 05, 2025

(ETON) Technical Data - news.stocktradersdaily.com

Apr 05, 2025
pulisher
Apr 05, 2025

Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma - MSN

Apr 05, 2025
pulisher
Apr 01, 2025

Eton sells overseas rights for hormone disorder drug (ETON) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Eton Pharma Out-Licenses International Rights To Increlex To Esteve Pharma - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Eton Pharmaceuticals out-licenses international rights to Increlex - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Eton Pharmaceuticals IncEsteve To Pay Eur4 Million Up Front For Increlex RightsSEC Filing - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Eton Pharmaceuticals licenses Increlex rights abroad - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Eton Pharmaceuticals licenses Increlex rights abroad By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Apr 01, 2025

Eton Pharmaceuticals Out-Licenses International Rights to Increlex® - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Major Pharma Deal: Eton's Smart Move Unlocks Global Market for Rare Disease Treatment - Stock Titan

Apr 01, 2025
pulisher
Mar 25, 2025

Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency… - Informazione.it

Mar 25, 2025
pulisher
Mar 22, 2025

Research Analysts Set Expectations for ETON Q2 Earnings - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus

Mar 22, 2025
pulisher
Mar 21, 2025

B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 19, 2025
pulisher
Mar 19, 2025

B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - MarketScreener

Mar 19, 2025
pulisher
Mar 19, 2025

Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo

Mar 19, 2025
pulisher
Mar 18, 2025

Eton Pharmaceuticals Reports Record Q4 Revenue Growth - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Eton Pharmaceuticals Reports Record Q4 2024 Revenue and Successful Product Launches Ahead of Investor Day Conference Call - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Eton Pharmaceuticals Achieves 16th Straight Quarter of Growth, Doubles Product Portfolio - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings Scheduled For March 18, 2025 - Benzinga

Mar 18, 2025
pulisher
Mar 17, 2025

Eton Pharmaceuticals (NASDAQ:ETON) shareholder returns have been incredible, earning 421% in 5 years - Simply Wall St

Mar 17, 2025
pulisher
Mar 16, 2025

(ETON) On The My Stocks Page - news.stocktradersdaily.com

Mar 16, 2025
pulisher
Mar 15, 2025

Eton Pharmaceuticals nears NDA submission for new drug By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch - Benzinga India

Mar 14, 2025
pulisher
Mar 14, 2025

Eton Pharma rises on study results for rare disease drug - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Eton's Diabetes Drug Candidate Passes Bioequivalence Study -March 14, 2025 at 07:21 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Eton Pharmaceuticals nears NDA submission for new drug - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Eagle-Tribune

Mar 14, 2025
pulisher
Mar 14, 2025

Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial - StockTitan

Mar 14, 2025
pulisher
Mar 10, 2025

Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India

Mar 10, 2025
pulisher
Mar 06, 2025

Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

Eton Pharmaceuticals (ETON) to Release Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Trading (ETON) With Integrated Risk Controls - news.stocktradersdaily.com

Mar 05, 2025
pulisher
Mar 04, 2025

Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN® - The Manila Times

Mar 04, 2025
$8.48
price up icon 0.47%
$27.00
price up icon 0.00%
$100.62
price down icon 0.69%
$7.57
price up icon 0.13%
$100.68
price down icon 0.69%
$284.25
price down icon 0.17%
Capitalizzazione:     |  Volume (24 ore):